This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.62% per year. These returns cover a period from January 1, 1988 through June 2, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
RARE's GTX-102 Gets FDA's Breakthrough Status for Angelman Syndrome
by Zacks Equity Research
Ultragenyx Pharmaceuticals' GTX-102 earns FDA Breakthrough status after early data shows sustained progress in Angelman syndrome patients.
BAYRYNegative Net Change AGENNegative Net Change RARENegative Net Change IMCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
BMY Loses 16.3% YTD: Should You Buy, Sell or Hold the Stock?
by Ekta Bagri
BMY loses 16.3% YTD as pipeline setbacks and generic pressure offset gains from new drug approvals and sales.
BMYNegative Net Change PFEPositive Net Change MRKPositive Net Change BNTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Vertex Down Around 9% in Three Months: Should You Buy, Sell or Hold the Stock?
by Kinjel Shah
VRTX slips 9% in three months on slow new drug uptake and pipeline hiccups, but CF strength and 2025 growth offer a reason to hold.
VRTXPositive Net Change MRNAPositive Net Change CRSPPositive Net Change
pharmaceuticals
NVO vs. LLY: Which Obesity Powerhouse is the Stronger Bet Now?
by Ahan Chakraborty
Eli Lilly edges ahead of Novo Nordisk as the stronger obesity bet, backed by robust sales growth, pipeline depth and strategic momentum.
NVOPositive Net Change LLYPositive Net Change AMGNPositive Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
PFE's Hympavzi Phase III Hemophilia Study With Inhibitors Meets Goal
by Zacks Equity Research
Pfizer's Hympavzi meets key phase III goals, demonstrating a significant reduction in bleeding in hemophilia patients with inhibitors.
PFEPositive Net Change BMRNNegative Net Change EXELPositive Net Change PBYIPositive Net Change
pharmaceuticals
Amgen Looks to Take Share of Booming Obesity Space: Will It Succeed?
by Kinjel Shah
Amgen aims to challenge obesity drug leaders with MariTide, a potential monthly treatment now in late-stage trials.
NVOPositive Net Change LLYPositive Net Change AMGNPositive Net Change VKTXNegative Net Change
pharmaceuticals
AbbVie Adds More Than $24B in 6 Months: How to Play ABBV Stock
by Kinjel Shah
ABBV adds $24B in market cap as Skyrizi and Rinvoq drive growth post-Humira, with more upside from a strong pipeline.
NVOPositive Net Change LLYPositive Net Change ABBVPositive Net Change
pharmaceuticals
Will Strong Asceniv Sales Drive ADMA Biologics Further?
by Ekta Bagri
ADMA rides on record Asceniv sales and FDA-backed yield boost, but valuation concerns and EPS downgrades cloud its outlook.
GRFSPositive Net Change ADMAPositive Net Change TAKPositive Net Change
biotechnology biotechs medical pharmaceuticals
3 Promising Genomics Stocks to Keep an Eye On in 2025
by Ekta Bagri
Investors interested in the Genomics and Synthetic Biology theme should keep an eye on MGTX, BEAM and KRYS.
BEAMPositive Net Change NTLANegative Net Change KRYSNegative Net Change MGTXNegative Net Change
cell-therapy gene-therapy genetics genomics medical pharmaceuticals
Will MRK's Growing Pipeline Help Navigate the Looming Keytruda LOE?
by Kanishka Das
Merck's growing pipeline, with nearly 20 new launches ahead, is set to reshape its portfolio as Keytruda's 2028 patent expiry nears.
AZNPositive Net Change RHHBYNegative Net Change BMYNegative Net Change MRKPositive Net Change
pharmaceuticals
Can LLY's Next-Generation Obesity Pipeline Fuel Further Growth?
by Ahan Chakraborty
Eli Lilly bets on next-generation obesity candidates like orforglipron and retatrutide to sustain growth amid rising competition.
NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
J&J's MedTech Segment Slowing Down: Will its Sales Recover in 2025?
by Kinjel Shah
JNJ's MedTech sales face pressure from China and competition but new products may lead to a stronger second half of 2025.
BSXPositive Net Change JNJPositive Net Change MDTPositive Net Change SYKPositive Net Change
pharmaceuticals
KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update
by Zacks Equity Research
Kymera's shares drop as Sanofi ends KT-474 development, but Gilead's oncology deal remains positive.
SNYPositive Net Change GILDPositive Net Change KYMRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Zacks.com featured highlights ASR, INSW, BCRX, ASC and RRGB
by Zacks Equity Research
ASR, INSW, and BCRX lead a high-efficiency stock screen with strong earnings surprises and solid fundamentals amid market volatility.
BCRXNegative Net Change ASRPositive Net Change RRGBPositive Net Change ASCNegative Net Change INSWNegative Net Change
pharmaceuticals
KRYS Up 4% on Initiating Dosing in Rare Eye Disease Phase III Study
by Zacks Equity Research
Krystal Biotech rises 4% after dosing begins in a phase III study of KB803 eye drops to treat rare DEB-related corneal damage.
BAYRYNegative Net Change AGENNegative Net Change KRYSNegative Net Change IMCRPositive Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
Amarin Soars 27% on Vazkepa Licensing Deal With Recordati in the EU
by Zacks Equity Research
AMRN jumps 27% after inking an exclusive EU licensing deal with Recordati to expand Vazkepa's reach and cut costs.
BAYRYNegative Net Change AGENNegative Net Change AMRNPositive Net Change IMCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?
by Sundeep Ganoria
CRSP edges ahead of NTLA with the only approved CRISPR therapy, stronger pipeline breadth and recent stock gains.
REGNPositive Net Change VRTXPositive Net Change NTLANegative Net Change CRSPPositive Net Change
biotechs crispr gene-editing gene-therapy genomics medical pharmaceuticals
Will New Drugs Enable BMY to Offset the Impact of Generic Competition?
by Ekta Bagri
BMY depends on Reblozyl, Opdualag and Breyanzi to offset revenue hits from generics and Medicare Part D impacts.
BMYNegative Net Change PFEPositive Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Sanofi's Experimental Transplant Rejection Drug Gets FDA Orphan Tag
by Zacks Equity Research
Sanofi's riliprubart gets FDA orphan drug status for organ transplant rejection, unlocking key development perks.
SNYPositive Net Change AGENNegative Net Change AMRNPositive Net Change IMCRPositive Net Change
biotechs medical pharmaceuticals
Merck Moves Past 50-Day Average: How to Play MRK Stock Now
by Kinjel Shah
MRK breaks above its 50-day average but near-term headwinds and weak China sales challenge the bullish case.
MRKPositive Net Change MRNAPositive Net Change SMMTPositive Net Change
pharmaceuticals
ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?
by Ekta Bagri
ADMA's surging Asceniv demand and bold revenue forecasts set it apart in the competitive plasma therapies space.
ADMAPositive Net Change TAKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Top Analyst Reports for JPMorgan, Novartis & AT&T
by Mark Vickery
JPM's strong NII outlook, NVS's blockbuster pipeline, and T's wireless momentum anchor today's top analyst picks.
JPMPositive Net Change NEENegative Net Change NVSPositive Net Change TPositive Net Change JCIPositive Net Change APHPositive Net Change UTMDNegative Net Change PPIHNegative Net Change
communications finance industrial-products medical pharmaceuticals
Can Hims Recover after Novo Nordisk Diss?
by David Bartosiak
Hims shares tumbled after Novo Nordisk canceled its partnership. Can the stock recover?
HIMSPositive Net Change
pharmaceuticals stock-performance
MRK's Winrevair Phase III Study in Newly Diagnosed PAH Meets Goal
by Zacks Equity Research
Merck's Winrevair meets goal in a phase III study in newly diagnosed PAH patients, showing strong efficacy.
JNJPositive Net Change MRKPositive Net Change UTHRPositive Net Change EXELPositive Net Change
pharmaceuticals
CHMP Backs NVO's Ozempic EU Label Update for Cardiovascular Indication
by Zacks Equity Research
CHMP recommends a label update for Novo Nordisk's Ozempic after the STRIDE study shows walking improvements in T2D patients with PAD.
NVOPositive Net Change BAYRYNegative Net Change AGENNegative Net Change IMCRPositive Net Change
biotechnology biotechs medical pharmaceuticals